Cargando…

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953461/ https://www.ncbi.nlm.nih.gov/pubmed/33631065 http://dx.doi.org/10.1056/NEJMoa2100433

Ejemplares similares

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group
por: Hermine, Olivier, et al.
Publicado: (2022)

Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis
por: Gorham, Julie, et al.
Publicado: (2020)

Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry
por: Amer, Marwa, et al.
Publicado: (2021)

The Combined Use of Interleukin-6 with Serum Albumin for Mortality Prediction in Critically Ill Elderly Patients: The Interleukin-6-to-albumin Ratio
por: Lim, Kai Yang, et al.
Publicado: (2022)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Interleukin6 prediction of mortality in critically ill COVID19 patients: A prospective observational cohort study
por: Jamoussi, Amira, et al.
Publicado: (2023)

Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies
por: Blanchetot, Christophe, et al.
Publicado: (2016)

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis
por: Li, Songsong, et al.
Publicado: (2016)

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
por: Zhang, Chi, et al.
Publicado: (2020)

Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
por: Jahaj, Edison, et al.
Publicado: (2021)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
por: Montesarchio, Vincenzo, et al.
Publicado: (2020)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022)

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
por: Tatham, Kate C., et al.
Publicado: (2021)

High Mobility Group Box 1 and Interleukin 6 at Intensive Care Unit Admission as Biomarkers in Critically Ill COVID-19 Patients
por: Sivakorn, Chaisith, et al.
Publicado: (2021)

Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer
por: Gong, Zhenqiang, et al.
Publicado: (2018)

Interleukin Expression after Injury and the Effects of Interleukin-1 Receptor Antagonist
por: Chamberlain, Connie S., et al.
Publicado: (2013)

Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient
por: Monneret, Guillaume, et al.
Publicado: (2020)

Physiologic role of interleukin-1 receptor antagonist
por: Arend, William P, et al.
Publicado: (2000)

Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Publicado: (2020)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients
por: Boyd, Sean, et al.
Publicado: (2021)

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse
por: Bjrök, P., et al.
Publicado: (1992)

Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
por: Nicklin, Martin J.H., et al.
Publicado: (2000)

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
por: Woxholt, Sindre, et al.
Publicado: (2023)

Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells
Publicado: (1994)

Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis
por: Bao, Jun, et al.
Publicado: (2014)

Metoprolol in Critically Ill Patients With COVID-19
por: Clemente-Moragón, Agustín, et al.
Publicado: (2021)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19
por: Luo, Kuan, et al.
Publicado: (2021)

Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
por: Di Nisio, Marcello, et al.
Publicado: (2021)

Critically ill COVID-19 patient
por: HALAÇLI, Burçin, et al.
Publicado: (2020)

COVID-19 in the Critically Ill Patient
por: Bell, Taison D.
Publicado: (2022)

Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)
por: Maslennikov, Roman, et al.
Publicado: (2021)

Comparison of 6-Month Outcomes of Survivors of COVID-19 versus Non–COVID-19 Critical Illness
por: Hodgson, Carol L., et al.
Publicado: (2022)

Amyloid formation disrupts the balance between interleukin-1β and interleukin-1 receptor antagonist in human islets
por: Hui, Queenie, et al.
Publicado: (2017)

Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy
por: Schwab, Kristin, et al.
Publicado: (2020)

A peptoid interleukin‐15 receptor antagonist suppresses inflammation and arthritis in mice
por: Cho, Kwang Bog, et al.
Publicado: (2022)

Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later
por: Gasnier, Matthieu, et al.
Publicado: (2022)

Interleukin 1-β, Interleukin-1 Receptor Antagonist, and Interleukin 18 in Children with Acute Spontaneous Urticaria
por: Machura, E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kn585q8qt42fbe6r3kj9vgl8pg